Announced
Completed
Financials
Sources
Tags
Single Bidder
Biotechnology
United States
biotechnology company
Private
Majority
Completed
Acquisition
Friendly
Cross Border
Synopsis
QIAGEN, a provider of sample to insight solutions, completed the acquisition of Verogen, a biotechnology company, for $150m. “Bringing together Verogen and QIAGEN creates a unique opportunity to better help investigators and researchers to advance forensic science and to find missing persons, accurately identify suspects and exonerate the innocent. The power of NGS has created so many applications that were not possible before, and its use in forensics is another opportunity for QIAGEN to provide the most complete workflow and help improve the lives of people around the world," Thierry Bernard, QIAGEN CEO.
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.